Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Oppenheimer analyst Jay Olson maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
bovnews2h
Viking Therapeutics Inc (VKTX) Stock: More Resilient Than It Appears
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...
Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...
Investor's Business Daily on MSN20h
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock rose early Tuesday after compounded weight-loss drugs helped build on a "robust" trajectory for Hims & Hers Health ...
Viking Therapeutics participates in a conference call with JPMorgan
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...
Investor's Business Daily on MSN23h
Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside'
Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...